181827-47-4

Basic information

• Product Name: N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE
• Synonyms: N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE;L-Proline,N-(methoxycarbonyl)-L-valyl;(S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidine-2-carboxylic acid;(S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidine-2-carboxylic acid(WXG02736)
• CAS NO: 181827-47-4
• Molecular Formula: C₁₂H₂₀N₂O₅
• Molecular Weight: 272.2976
• Mol File: 181827-47-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 490.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.244±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.60±0.20(Predicted)
• CAS DataBase Reference: N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE(181827-47-4)
• EPA Substance Registry System: N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE(181827-47-4)

Safety Data

• Hazardous Substances Data: 181827-47-4(Hazardous Substances Data)

Usage

General Description

N-(Methoxycarbonyl)-L-valyl]-L-proline is a chemical compound that belongs to the class of organic compounds known as proline and derivatives. It is a synthetic analog of the bacterial cell wall precursor Lipid II, making it a potential therapeutic target for drug development against bacterial infections. N-(METHOXYCARBONYL)-L-VALYL]-L-PROLINE has also been studied for its potential use in cancer treatment, as it has been found to inhibit the growth of cancer cells by disrupting the microtubule network. Additionally, N-(Methoxycarbonyl)-L-valyl]-L-proline has been investigated for its anti-inflammatory properties and its potential to modulate the immune response.

Upstream product

• 2577-48-2 methyl (2S)-pyrrolidine carboxylate 
• 147-85-3 L-proline 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 112175-14-1 Moc-L-Val-O-COOMe 
• 1258232-91-5 (S,S)-1-(2-methoxycarbonylamino-3-methylbutyryl)pyrrolidine-2-carboxylic acid benzyl ester 
• 72-18-4 L-valine 
• 1312610-98-2 C₁₃H₂₂N₂O₅ 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 1272655-85-2 2-(4'-(((((2S)-1-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-2-pyrrolidinyl)carbonyl)oxy)acetyl)-4-biphenylyl)-2-oxoethyl(3S)-8,8-difluoro-2-((2S)-3-methyl-2-(((methyloxy)carbonyl)amino)butanoyl)-2-azaspiro[4.5]dec-3-carboxylate 
• 1312611-05-4 C₁₈H₂₆BN₃O₆ 
• 1312609-19-0 C₃₇H₄₇N₇O₈S 
• 1312611-06-5 C₃₃H₄₀N₄O₆ 
• 1312611-07-6 C₂₈H₃₂N₄O₄ 
• 1256387-27-5 C₃₇H₄₉N₇O₉ 
• 1312609-60-1 C₂₅H₂₉N₅O₇ 
• 1312610-99-3 C₂₅H₃₁N₅O₅ 
• 1312610-00-6 C₄₂H₅₁N₅O₁₂S 
• 1312610-12-0 C₄₁H₅₀N₄O₁₄ 
• 1312610-41-5 C₄₃H₅₂N₄O₁₃ 
• 1312610-45-9 C₄₀H₄₈N₆O₁₂S 
• 1312610-51-7 C₄₁H₄₉N₅O₁₂S 
• 1312608-51-7 C₄₄H₅₆N₄O₁₂ 

Relevant articles and documents

5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Preparation method for daclatasvir

The invention discloses a preparation method for daclatasvir. The preparation method comprises the following steps: in a solvent, performing a cyclization reaction on a compound shown as a formula D10 and ammonium acetate, so as to prepare the daclatasvir shown as a formula I, wherein the cyclization reaction is shown in the description. The preparation method for daclatasvir is low in cost, high in yield, friendly to environment, simple in steps, mild in reaction conditions and suitable for industrialized production.

Novel synthesis method of Daclatasvir

The invention relates to a novel synthesis method of Daclatasvir, particularly discloses an intermediate for preparing Daclatasvir and a preparation method of the intermediate, and provides a preparation method of Daclatasvir. The method is more economical and more efficient.